AdAPT™ Immunotherapy Platform
To Catch an Apex Predator: AdAPT-001 and TGF-β
AdAPT™ Platform Manufacturability
The manufacture of pharmaceutical grade gene therapy vectors at the scale needed for large phase trials and commercialization has historically been a rate-limiting bottleneck with prohibitively long lead times. Thanks to the unique expertise of dedicated EpicentRx personnel, the company has developed a robust, high-titer process suitable for clinical studies all within its own GMP facility.